Amniotic Injections
Our amniotic injections come from our suppliers and arrive cryopreserved or at ambient temperature to our providers. The injections are via a cash pay model. Our injections are scientifically proven to not only arrest the symptoms of arthritis by stopping the degeneration of cartilage but are backed in clinical trials to rebuild cartilage. Our injections through are currently being tested for arthritis of the knee, hips, and ankle and are proving to be four times more effective than hyaluronic acid injections and twice as effective as PRP injections. They also have additional applications for ACL/MCL/meniscal tears, rotator cuff tears, ankle ligament tears, plantar fasciitis, and trigger finger, to name but a few. Clinical studies are showing that improvement is at 80% with reductions in inflammation, pain, and improvement in joint function at 1 year with 1 injection.
Properties of amniotic membrane injections
- Mechanical cushioning and support
- Lubrication for movement
- Suppression of inflammation
- Promotes skeletal, muscular, and organ development
- Contain an unique mix of collagen, extracellular matrix proteins, cell adhesion molecules, anti-inflammatory cytokines, and growth factors
Growth Factors
- Fibroblast Growth Factor (FGF)
- Epidermal Growth Factor (EGF)
- Platelet derived Growth Factor (PDGF A&B)
- Vascular Endothelial Growth Factor (VEGF)
- Transforming Growth Factor Beta (TGF-beta)
Properties of amniotic membrane
- Anti-inflammatory
- Anti-bacterial
- Anti-viral
- Anti-microbial
- Anti-fibrotic
- Re-epithelization
- Anti-scarring
- Non-tumorigenic
Physical Scaffold
Amniotic tissue can stimulate the delivery of growth factors, cellular response, collagen and a physical scaffold on which wound repair and regeneration can occur.
History of amniotic tissue therapy
Amniotic tissue has been used in clinical settings for over a 100 years to care for wounds, including burns, skin ulcerations, and soft tissue trauma. It was first documented in the 1900's as a skin substitute for wound and reconstructive purposes.
FDA classification
As long as amniotic tissue is:
- Minimally manipulated
- Intended for homologous use
- Not combined with a drug or device
- Has a localized effect
- Is not dependent on metabolic cells for its primary function
It is classified as a Human Cell, Tissue, and Cellular and Tissue-based Product (HCT/Ps) regulated solely under section 361 of the PHS act and 21 CFR part 1271 if it meets all of the following above criteria.
During processing
Our amniotic tissue is:
- Cleaned
- Tested for all known bacterial, fungal, and viral pathogens.
- Sourced from mothers after undergoing stringent medical and social history screening.
- All original relevant characteristics of the tissue are not altered.
- Blood components removed
- Sterilized
- Separated from the chorion layer
- Prepared for use as an allograft
- All processed tissues are tested per US Pharmacopeia Convention guidelines prior to release.
- Our suppliers carry the highest accreditation by the American Association of Tissue Banks (AATB).
